Characterization of increased drug metabolism activity in dimethyl sulfoxide (DMSO)-treated Huh7 hepatoma cells

References

• Alexandre E, Davida P, Viollonb C, Wolfa P, Jaecka D, Azimzadeha A, Nicodb L, Boudjemaa K, Richertb L. 1999. Expression of cytochromes P-450 2E1, 3A4 and 1A1/1A2 in growing and confluent human HepG2 hepatoma cells — effect of ethanol. Toxicol In Vitro 13:427–435.
   PubMed Web of Science ®Google Scholar
• Aninat C, Piton A, Glaise D, Le Charpentier T, Langouet S, Morel F, Guguen-Guillouzo C, Guillouzo A. 2006. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos 34:75–83.
   PubMed Web of Science ®Google Scholar
• Barbier O, Duran-Sandoval D, Pineda-Torra I, Kosykh V, Fruchart JC, Staels B. 2003. Peroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme. J Biol Chem 278:32852–32860.
   PubMed Web of Science ®Google Scholar
• Bowen WP, Carey JE, Miah A, McMurray HF, Munday PW, James RS, Coleman RA, Brown AM. 2000. Measurement of cytochrome P450 gene induction in human hepatocytes using quantitative real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 28:781–788.
   PubMed Web of Science ®Google Scholar
• Castell JV, Gomez-Lechon MJ, Ponsoda X, Bort R. 1997. The use of cultured hepatocytes to investigate the mechanisms of drug hepatotoxicity. Cell Biol Toxicol 13:331–338.
   PubMedGoogle Scholar
• Chomczynski P, Sacchi N. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate–phenol–chloroform extraction. Anal Biochem 162:156–159.
   PubMed Web of Science ®Google Scholar
• Csala M, Staines AG, Banhegyi G, Mandl J, Coughtrie MW, Burchell B. 2004. Evidence for multiple glucuronide transporters in rat liver microsomes. Biochem Pharmacol 68:1353–1362.
   PubMedGoogle Scholar
• Deeley RG, Westlake C, Cole SP. 2006. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 86:849–899.
   PubMed Web of Science ®Google Scholar
• Donato MT, Castell JV, Gomez-Lechon MJ. 1995. Effect of model inducers on cytochrome P450 activities of human hepatocytes in primary culture. Drug Metab Dispos 23:553–558.
   PubMed Web of Science ®Google Scholar
• Duverlie G, Wychowski C. 2007. Cell culture systems for the hepatitis C virus. World J Gastroenterol 13:2442–2445.
   PubMedGoogle Scholar
• Gardner-Stephen D, Heydel JM, Goyal A, Lu Y, Xie W, Lindblom T, Mackenzie P, Radominska-Pandya A. 2004. Human PXR variants and their differential effects on the regulation of human UDP-glucuronosyltransferase gene expression. Drug Metab Dispos 32:340–347.
   PubMed Web of Science ®Google Scholar
• Goldring CE, Kitteringham NR, Jenkins R, Lovatt CA, Randle LE, Abdullah A, Owen A, Liu X, Butler PJ, Williams DP et al. 2006. Development of a transactivator in hepatoma cells that allows expression of Phase I, Phase II, and chemical defense genes. Am J Physiol Cell Physiol 290:C104–C115.
   PubMedGoogle Scholar
• Gomez-Lechon MJ, Castell JV, Donato MT. 2007. Hepatocytes — the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo. Chem Biol Interact 168:30–50.
   PubMed Web of Science ®Google Scholar
• Gomez-Lechon MJ, Donato MT, Castell JV, Jover R. 2004. Human hepatocytes in primary culture: the choice to investigate drug metabolism in man. Curr Drug Metab 5:443–462.
   PubMed Web of Science ®Google Scholar
• Gottwein JM, Scheel TK, Hoegh AM, Lademann JB, Eugen-Olsen J, Lisby G, Bukh J. 2007. Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/JFH1) viruses. Gastroenterology 133:1614–1626.
   PubMed Web of Science ®Google Scholar
• Guillouzo A, Corlu A, Aninat C, Glaise D, Morel F, Guguen-Guillouzo C. 2007. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem Biol Interact 168:66–73.
   PubMed Web of Science ®Google Scholar
• Gunton JE, Delhanty PJ, Takahashi S, Baxter RC. 2003. Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2. J Clin Endocrinol Metab 88:1323–1332.
   PubMed Web of Science ®Google Scholar
• Hakooz N, Ito K, Rawden H, Gill H, Lemmers L, Boobis AR, Edwards RJ, Carlile DJ, Lake BG, Houston JB. 2006. Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance. Pharm Res 23:533–539.
   PubMed Web of Science ®Google Scholar
• Hallifax D, Rawden HC, Hakooz N, Houston JB. 2005. Prediction of metabolic clearance using cryopreserved human hepatocytes: kinetic characteristics for five benzodiazepines. Drug Metab Dispos 33:1852–1858.
   PubMed Web of Science ®Google Scholar
• Hewes JC, Riddy D, Morris RW, Woodrooffe AJ, Davidson BR, Fuller B. 2006. A prospective study of isolated human hepatocyte function following liver resection for colorectal liver metastases: the effects of prior exposure to chemotherapy. J Hepatol 45:263–270.
   PubMedGoogle Scholar
• Hewitt NJ, Hewitt P. 2004. Phase I and II enzyme characterization of two sources of HepG2 cell lines. Xenobiotica 34:243–256.
   PubMed Web of Science ®Google Scholar
• Huang H, Chen Y, Ye J. 2007. Inhibition of hepatitis C virus replication by peroxidation of arachidonate and restoration by vitamin E. Proc Natl Acad Sci USA 104:18666–18670.
   PubMed Web of Science ®Google Scholar
• Kanebratt KP, Andersson TB. 2008. Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab Dispos 36:1444–1452.
   Google Scholar
• Kogure T, Ueno Y, Iwasaki T, Shimosegawa T. 2004. The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. Cancer Chemother Pharmacol 53:296–304.
   PubMedGoogle Scholar
• Ledirac N, de Sousa G, Fontaine F, Agouridas C, Gugenheim J, Lorenzon G, Rahmani R. 2000. Effects of macrolide antibiotics on CYP3A expression in human and rat hepatocytes: interspecies differences in response to troleandomycin. Drug Metab Dispos 28:1391–1393.
   PubMed Web of Science ®Google Scholar
• Li AP, Reith MK, Rasmussen A, Gorski JC, Hall SD, Xu L, Kaminski DL, Cheng LK. 1997. Primary human hepatocytes as a tool for the evaluation of structure–activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. Chem Biol Interact 107:17–30.
   PubMed Web of Science ®Google Scholar
• Ma Q, Lu AY. 2007. CYP1A induction and human risk assessment: an evolving tale of in vitro and in vivo studies. Drug Metab Dispos 35:1009–1016.
   PubMed Web of Science ®Google Scholar
• Mankowski DC. 1999. The role of CYP2C19 in the metabolism of (+/–) bufuralol, the prototypic substrate of CYP2D6. Drug Metab Dispos 27:1024–1028.
   PubMed Web of Science ®Google Scholar
• Martignoni M, Groothuis GM, de Kanter R. 2006. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875–894.
   PubMed Web of Science ®Google Scholar
• Morgan ET. 2001. Regulation of cytochrome p450 by inflammatory mediators: why and how? Drug Metab Dispos 29:207–212.
   PubMed Web of Science ®Google Scholar
• Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. 1982. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 42:3858–3863.
   PubMed Web of Science ®Google Scholar
• Olsavsky KM, Page JL, Johnson MC, Zarbl H, Strom SC, Omiecinski CJ. 2007. Gene expression profiling and differentiation assessment in primary human hepatocyte cultures, established hepatoma cell lines, and human liver tissues. Toxicol Appl Pharmacol 222:42–56.
   PubMed Web of Science ®Google Scholar
• Pascussi JM, Gerbal-Chaloin S, Duret C, Daujat-Chavanieu M, Vilarem MJ, Maurel P. 2008. The tangle of nuclear receptors that controls xenobiotic metabolism and transport: crosstalk and consequences. Annu Rev Pharmacol Toxicol 48:1–32.
   PubMed Web of Science ®Google Scholar
• Phillips A, Hood SR, Gibson GG, Plant NJ. 2005. Impact of transcription factor profile and chromatin conformation on human hepatocyte CYP3A gene expression. Drug Metab Dispos 33:233–242.
   PubMedGoogle Scholar
• Radominska-Pandya A, Bratton S, Little JM. 2005. A historical overview of the heterologous expression of mammalian UDP-glucuronosyltransferase isoforms over the past twenty years. Curr Drug Metab 6:141–160.
   PubMed Web of Science ®Google Scholar
• Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG, Miners JO. 2006. In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine–valproic acid interaction. Drug Metab Dispos 34:1055–1062.
   PubMed Web of Science ®Google Scholar
• Sainz B, Jr, Chisari FV. 2006. Production of infectious hepatitis C virus by well-differentiated, growth-arrested human hepatoma- derived cells. J Virol 80:10253–10257.
   PubMed Web of Science ®Google Scholar
• Takagi S, Nakajima M, Mohri T, Yokoi T. 2008. Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J Biol Chem 283:9674–9680.
   PubMed Web of Science ®Google Scholar
• Tassaneeyakul W, Birkett DJ, McManus ME, Veronese ME, Andersson T, Tukey RH, Miners JO. 1994. Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. Biochem Pharmacol 47:1767–1776.
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, Obach RS, Rostami-Hodjegan A. 2007. Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug–drug interaction risk assessment. Xenobiotica 37:1225–1256.
   PubMed Web of Science ®Google Scholar
• Von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Venkatakrishnan K, Schmider J, Harmatz JS, Shader RI. 1998. Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. J Pharm Pharmacol 50:997–1004.
   PubMed Web of Science ®Google Scholar
• Wadelius M, Darj E, Frenne G, Rane A. 1997. Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther 62:400–407.
   PubMed Web of Science ®Google Scholar
• Wilson ZE, Rostami-Hodjegan A, Burn JL, Tooley A, Boyle J, Ellis SW, Tucker GT. 2003. Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. Br J Clin Pharmacol 56:433–440.
   PubMed Web of Science ®Google Scholar
• Yu A, Haining RL. 2001. Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities? Drug Metab Dispos 29:1514–1520.
   PubMed Web of Science ®Google Scholar
• Yuan R, Madani S, Wei XX, Reynolds K, Huang SM. 2002. Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 30:1311–1319.
   PubMed Web of Science ®Google Scholar
• Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV. 2005. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 102:9294–9299.
   PubMed Web of Science ®Google Scholar